Tech Company Financing Transactions

Affymax Funding Round

Bessemer Venture Partners, Apax Partners and Merlin BioMed Group participated in a $60 million Series D funding round for Affymax. The round was announced on 7/18/2005.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series D
Proceeds Purpose
The proceeds will give us the ability to aggressively move forward with our Phase 2 clinical program for Hematide in patients with chronic kidney disease and cancer, as well as develop our pipeline of promising peptide product candidates.

Company Information

Company Status
Out of Business
Mailing Address
19200 Stevens Creek Blvd. 240
Cupertino, CA 95014
Email Address
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions.
Affymax LinkedIn Company Profile
Social Media
Affymax Company Twitter Account
Company News
Affymax News
Affymax on Facebook
Affymax on YouTube

Management Team

Email & Social
Chief Financial Officer
Mark Thompson
  Mark Thompson LinkedIn Profile  Mark Thompson Twitter Account  Mark Thompson News  Mark Thompson on Facebook
VP - Finance
Karin Walker
  Karin Walker LinkedIn Profile  Karin Walker Twitter Account  Karin Walker News  Karin Walker on Facebook
VP - General Counsel
Tracy Dunn
  Tracy Dunn LinkedIn Profile  Tracy Dunn Twitter Account  Tracy Dunn News  Tracy Dunn on Facebook



Browse more venture capital transactions:

Prev: 7/18/2005: Zazzle venture capital transaction
Next: 7/19/2005: Zoom Systems venture capital transaction


Share this article


Where The Data Comes From

We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary